VBCR - June 2017, Vol 6, No 2
Quality and Efficacy of Mobile Applications for Measuring and Recording Rheumatoid Arthritis Disease Activity
Based on the results of their study, Dr Grainger and colleagues asserted that current mobile applications available to assist in the management of patients with RA are configured as simple calculators for rheumatologists or as data tracking tools for patients, and the latter do not uniformly collect data using validated instruments.
Using Social Media to Research Arthritis Drug Safety and Efficacy, and Determine the Impact of Advertisements
Based on data accessed in May 2016 from Symplur, a platform that maintains a controlled database of vetted healthcare hashtags grouped with other relevant hashtags, the most common sources for mentions of rheumatoid arthritis on Twitter included a mix of professional patient advocacy organizations and individual patients.
In a recent interview with Value-Based Care in Rheumatology (VBCR), Umbreen Hasan, MD, MBA, FACR, FACP, Consulting Rheumatologist, Minneapolis, MN, and member of the VBCR Editorial Advisory Board, discussed the diagnosis and treatment of Sjögren’s syndrome.
Dr Verstappen and colleagues had previously shown that patients treated within 6 months of symptom onset had improved 10-year outcomes compared with those who were treated later.
Discontinuing Adalimumab Is Feasible for Some Patients with Rheumatoid Arthritis Who Have Achieved Low Disease Activity
To determine whether adalimumab discontinuation yields results similar to continuation of adalimumab over a longer period, Dr Tanaka and colleagues conducted the HOPEFUL-3 study.
The efficacy of tocilizumab in combination with methotrexate and as monotherapy was maintained for 2 years in patients with early rheumatoid arthritis (RA), according to an analysis of the results of the FUNCTION trial (Burmester G, et al. Ann Rheum Dis. 2017. Epub ahead of print). No new safety signals associated with tocilizumab were reported with longer- term follow-up of this trial.
“The objectives of the study were to determine whether hospital admission with an autoimmune disease is associated with future admission with dementia more often than expected by chance,” the research explained.
To reduce gout flares, colchicine or a nonsteroidal anti-inflammatory drug was given 14 days before baseline through month 5, unless patients could not tolerate these prophylactic drugs.
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17